Trial Profile
A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptive vaginal ring delivering a daily dose of 150 Ug of Nestorone [elcometrine] and 15 Ug of ethinyl estradiol
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Estradiol/elcometrine (Primary)
- Indications Pregnancy
- Focus Adverse reactions; Registrational; Therapeutic Use
- 03 May 2021 Pooled results published in TherapeuticsMD Media Release
- 03 May 2021 According to a Therapeutics MD media release, results pooled from this trial was presented at 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting conducted virtually from April 30 to May 2, 2021.
- 06 Aug 2019 Results describing bleeding patterns among users of the segesterone acetate andethinyl estradiol contraceptive vaginal system (CVS), and identifying factors associated with unscheduled bleeding/spotting (B/S) using pooled data from 2 trials (NCT00263341, NCT00455156) published in the Contraception